Please Wait
Applying Filters...
Menu
Xls
2D Structure
Also known as: 143443-90-7, Bms-180291, Ifetroban [usan:inn], Unii-e833kt807k, 3-[2-[[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid, Bms 180291-02
Molecular Formula
C25H32N2O5
Molecular Weight
440.5  g/mol
InChI Key
BBPRUNPUJIUXSE-DXKRWKNPSA-N
FDA UNII
E833KT807K

IFETROBAN is a small molecule drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-[2-[[(1S,2R,3S,4R)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic acid
2.1.2 InChI
InChI=1S/C25H32N2O5/c1-2-3-6-13-26-24(30)19-15-31-25(27-19)23-18(20-10-11-21(23)32-20)14-17-8-5-4-7-16(17)9-12-22(28)29/h4-5,7-8,15,18,20-21,23H,2-3,6,9-14H2,1H3,(H,26,30)(H,28,29)/t18-,20-,21+,23-/m0/s1
2.1.3 InChI Key
BBPRUNPUJIUXSE-DXKRWKNPSA-N
2.2 Other Identifiers
2.2.1 UNII
E833KT807K
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 180291

2. Bms-180291

3. Bms180291

2.3.2 Depositor-Supplied Synonyms

1. 143443-90-7

2. Bms-180291

3. Ifetroban [usan:inn]

4. Unii-e833kt807k

5. 3-[2-[[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl]phenyl]propanoic Acid

6. Bms 180291-02

7. E833kt807k

8. Ifetroban [inn]

9. Ifetroban [usan]

10. Bms 180291

11. Dtxsid40869931

12. Benzenepropanoic Acid, 2-((3-(4-((pentylamino)carbonyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)-, (1s-(exo,exo))-

13. Bms 180,291

14. 3-[2-[[(1s,4r,5s,6r)-5-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-6-yl]methyl]phenyl]propanoic Acid

15. O-((1s,2r,3s,4r)-3-(4-(pentylcarbamoyl)-2-oxazolyl)-7-oxabicyclo(2.2.1)hept-2-yl)methyl)hydrocinnamic Acid

16. Ifetrobanum

17. 3-(2-(((1s,2r,3s,4r)-3-(4-(pentylcarbamoyl)-1,3-oxazol-2-yl)-7-oxabicyclo(2.2.1)heptan-2-yl)methyl)phenyl)propanoic Acid

18. 3-(2-(((1s,4r,5s,6r)-5-(4-(pentylcarbamoyl)-1,3-oxazol-2-yl)-7-oxabicyclo(2.2.1)heptan-6-yl)methyl)phenyl)propanoic Acid

19. 3-(2-{[(1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-1,3-oxazol-2-yl]-7-oxabicyclo[2.2.1]heptan-2-yl]methyl}phenyl)propanoic Acid

20. O-[[1s,2r,3s,4r)-3-[4-(pentylcarbamoyl)-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]hydrocinnamic Acid

21. Bms180291

22. Schembl28135

23. Gtpl1987

24. Chembl3301673

25. Dtxcid30820733

26. Chebi:188730

27. Bdbm50212318

28. Akos040748563

29. Db12321

30. Da-74420

31. Hy-105218

32. Cs-0025381

33. Ns00069206

34. Q5991162

2.4 Create Date
2005-08-09
3 Chemical and Physical Properties
Molecular Weight 440.5 g/mol
Molecular Formula C25H32N2O5
XLogP34
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count11
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area102
Heavy Atom Count32
Formal Charge0
Complexity644
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)